← Leaderboards
Robert C Rostomily
University Of Washington
$7,796,190
Attributed
$12,334,148
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,334,148 · 11
By mechanism
R01$7,731,563 · 4
U01$1,983,331 · 1
R21$1,376,054 · 3
K08$610,632 · 1
R61$463,811 · 1
R03$168,757 · 1
Top collaborators
- Karol Bomsztyk5 shared
- Albert Folch5 shared
- Raymond J Monnat5 shared
- Andrei M Mikheev3 shared
- Stephen H Safe3 shared
- Philip J Horner2 shared
- Francois St-Pierre2 shared
- Monika Vishnoi1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Karol Bomsztyk$10,331,951
- Andrei M Mikheev$999,466
- Adam K Glaser$2,814,284
- Philip J Horner$7,784,899
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant - DescriptorMalignant NeoplasmsGliomaIn VivoGlioblastomaPhenotypeCellsMalignant Neoplasm Of BrainStem CellsGene ExpressionGrowthResistanceTreatment ResponseClinically RelevantIn VitroInnovationRegulationPharmaceutical PreparationsBrain NeoplasmsBrainCell LineMediatingProperty
Grant awards (37)
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$554,314
R01 · FY2025 · NS · contact PI
A multiplexed high-throughput platform to report pharmacologic alteration of cancer stem cell membrane potential and cell cycle state$223,327
R61 · FY2025 · CA · contact PI
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$511,747
R01 · FY2024 · NS · contact PI
Patterned optogenetic neuromodulation to reprogram glioma stem cells$444,125
R21 · FY2024 · NS · contact PI
Development of a pre-clinical syngeneic pig glioma model for research and translational studies$415,257
R21 · FY2024 · CA · contact PI
Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay$376,747
U01 · FY2024 · CA
A multiplexed high-throughput platform to report pharmacologic alteration of cancer stem cell membrane potential and cell cycle state$240,484
R61 · FY2024 · CA · contact PI
âPharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment responseâ$503,363
R01 · FY2023 · NS · contact PI
Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay$405,793
U01 · FY2023 · CA
Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay$389,136
U01 · FY2022 · CA
Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay$397,078
U01 · FY2021 · CA
Influence of Pre-Analytical Factors in Globlastoma MGMT Promoter Methylation Biomarker Assay$414,577
U01 · FY2020 · CA
Therapeutically relevant targets of Twist1 dimers in glioma$353,281
R01 · FY2020 · NS · contact PI
Therapeutically relevant targets of Twist1 dimers in glioma$353,281
R01 · FY2019 · NS · contact PI
Microfluidic Device to Profile Chemosensitivity in Glioma Slice Cultures$532,112
R01 · FY2018 · CA
Microfluidic Device to Profile Chemosensitivity in Glioma Slice Cultures$532,112
R01 · FY2017 · CA
Therapeutically relevant targets of Twist1 dimers in glioma$349,271
R01 · FY2017 · NS · contact PI
Microfluidic Device to Profile Chemosensitivity in Glioma Slice Cultures$532,112
R01 · FY2016 · CA
Therapeutically relevant targets of Twist1 dimers in glioma$380,625
R01 · FY2016 · NS · contact PI
Microfluidic Device to Profile Chemosensitivity in Glioma Slice Cultures$532,112
R01 · FY2015 · CA
Therapeutically relevant targets of Twist1 dimers in glioma$380,625
R01 · FY2015 · NS · contact PI
TWIST1 as a target for inhibition of glioma invasion$344,450
R01 · FY2015 · CA · contact PI
Microfluidic Device to Profile Chemosensitivity in Glioma Slice Cultures$525,358
R01 · FY2014 · CA
TWIST1 as a target for inhibition of glioma invasion$334,117
R01 · FY2014 · CA · contact PI
TWIST1 as a target for inhibition of glioma invasion$323,783
R01 · FY2013 · CA · contact PI
Chronic versus acute effects of p53 deletion on Olig2 progenitor malignancy$82,215
R03 · FY2013 · AG · contact PI
TWIST1 as a target for inhibition of glioma invasion$344,450
R01 · FY2012 · CA · contact PI
Chronic versus acute effects of p53 deletion on Olig2 progenitor malignancy$86,542
R03 · FY2012 · AG · contact PI
TWIST1 as a target for inhibition of glioma invasion$344,450
R01 · FY2011 · CA · contact PI
Modeling gliomagenesis with aging glial progenitor cells and hosts$156,000
R21 · FY2009 · AG · contact PI
Modeling gliomagenesis with aging glial progenitor cells and hosts$194,922
R21 · FY2008 · AG · contact PI
Modeling gliomagenesis with aging glial progenitor cells and hosts$165,750
R21 · FY2007 · AG · contact PI
THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY$125,253
K08 · FY2004 · NS
THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY$125,253
K08 · FY2003 · NS
THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY$125,253
K08 · FY2002 · NS
THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY$125,253
K08 · FY2001 · NS
THE ROLE OF BHLH GENES IN GLIOGENESIS AND GLIOMA BIOLOGY$109,620
K08 · FY2000 · NS